138 related articles for article (PubMed ID: 17430192)
21. Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).
Kohn FR; Sladek NE
Biochem Pharmacol; 1987 Sep; 36(17):2805-11. PubMed ID: 2820422
[TBL] [Abstract][Full Text] [Related]
22. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine.
Bruntsch U; Groos G; Hiller TA; Wandt H; Tigges FJ; Gallmeier WM
Invest New Drugs; 1985; 3(3):293-6. PubMed ID: 4066222
[TBL] [Abstract][Full Text] [Related]
23. Causes and possibilities to circumvent cyclophosphamide toxicity.
Voelcker G
Anticancer Drugs; 2020 Jul; 31(6):617-622. PubMed ID: 32044797
[TBL] [Abstract][Full Text] [Related]
24. Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.
Giaccone G; Smit EF; de Jonge M; Dansin E; Briasoulis E; Ardizzoni A; Douillard JY; Spaeth D; Lacombe D; Baron B; Bachmann P; Fumoleau P;
Eur J Cancer; 2004 Mar; 40(5):667-72. PubMed ID: 15010066
[TBL] [Abstract][Full Text] [Related]
25. An in vitro cytotoxicity of glufosfamide in HepG2 cells relative to its nonconjugated counterpart.
Ahmed DE; Rashidi FB; Abdelhakim HK; Mohamed AS; Arafa HMM
J Egypt Natl Canc Inst; 2021 Aug; 33(1):22. PubMed ID: 34423383
[TBL] [Abstract][Full Text] [Related]
26. Glufosfamide (Baxter Oncology).
Niculescu-Duvaz I
Curr Opin Investig Drugs; 2002 Oct; 3(10):1527-32. PubMed ID: 12431031
[TBL] [Abstract][Full Text] [Related]
27. Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity.
Voelcker G
Anticancer Drugs; 2018 Jan; 29(1):75-79. PubMed ID: 29219879
[TBL] [Abstract][Full Text] [Related]
28. Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
Giraud B; Hebert G; Deroussent A; Veal GJ; Vassal G; Paci A
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):919-38. PubMed ID: 20446865
[TBL] [Abstract][Full Text] [Related]
29. Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent.
Dollner R; Dietz A; Kopun M; Helbig M; Wallner F; Granzow C
Anticancer Res; 2004; 24(5A):2947-51. PubMed ID: 15517901
[TBL] [Abstract][Full Text] [Related]
30. Comparative effects of new generation oxazaphosphorines on the size and viability of human acute myeloblastic leukemia cells.
Mazur L; Opydo-Chanek M; Wojcieszek K; Stojak M; Niemeyer U
Folia Biol (Krakow); 2012; 60(1-2):35-40. PubMed ID: 22428304
[TBL] [Abstract][Full Text] [Related]
31. [Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
Burkert H; Schnitker J; Fichtner E
MMW Munch Med Wochenschr; 1979 Jun; 121(22):760-2. PubMed ID: 112422
[TBL] [Abstract][Full Text] [Related]
32. [Perfect drug targeting. Glufosfamide a new derivative].
Holzgrabe U
Pharm Unserer Zeit; 2006; 35(2):158-9. PubMed ID: 16583570
[No Abstract] [Full Text] [Related]
33. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
Struck RF; Dykes DJ; Corbett TH; Suling WJ; Trader MW
Br J Cancer; 1983 Jan; 47(1):15-26. PubMed ID: 6821629
[TBL] [Abstract][Full Text] [Related]
34. Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies.
Skarbek C; Delahousse J; Pioche-Durieu C; Baconnais S; Deroussent A; Renevret P; Rivard M; Desmaele D; Martens T; Le Cam E; Couvreur P; Paci A
Int J Pharm; 2017 Nov; 532(2):748-756. PubMed ID: 28546071
[TBL] [Abstract][Full Text] [Related]
35. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance.
Sreerama L; Sladek NE
Cancer Res; 1994 Apr; 54(8):2176-85. PubMed ID: 8174125
[TBL] [Abstract][Full Text] [Related]
36. Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.
Wang D; Wang H
Acta Pharm Sin B; 2012 Apr; 2(2):. PubMed ID: 24349963
[TBL] [Abstract][Full Text] [Related]
37. Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine.
Maki PA; Sladek NE
Cancer Res; 1991 Aug; 51(16):4170-5. PubMed ID: 1868438
[TBL] [Abstract][Full Text] [Related]
38. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group.
Briasoulis E; Pavlidis N; Terret C; Bauer J; Fiedler W; Schöffski P; Raoul JL; Hess D; Selvais R; Lacombe D; Bachmann P; Fumoleau P
Eur J Cancer; 2003 Nov; 39(16):2334-40. PubMed ID: 14556925
[TBL] [Abstract][Full Text] [Related]
39. Stem cell toxicity of oxazaphosphorine metabolites in comparison to their antileukemic activity.
Brueggemann SK; Schlenke P; Klich S; Deeken M; Peters SO; Wagner T
Biochem Pharmacol; 2002 Apr; 63(7):1337-41. PubMed ID: 11960610
[TBL] [Abstract][Full Text] [Related]
40. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines.
Kohn FR; Sladek NE
Biochem Pharmacol; 1985 Oct; 34(19):3465-71. PubMed ID: 2996550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
